We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


DefiniGEN Appoints Chairman to Further Expand Preclinical Drug Development Capabilities

 DefiniGEN Appoints Chairman to Further Expand Preclinical Drug Development Capabilities content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

DefiniGEN has announced the appointment of Dr Ben Cons as Chairman of the Board. A respected entrepreneur and pharmaceutical and healthcare leader, he has a proven track record and brings more than 30 years’ experience in pharmaceutical R&D & commercialization across the biotech, pharmaceutical and financing sectors.

Dr Cons previously spent 20 years with the NYSE listed pharmaceutical services company IQVIA and the associated NovaQuest investment fund. He is currently a Special Partner at the private equity fund Vitruvian: Chairman of Castor EDC a medical research SaaS tool provider; Chairman of Charnwood Molecular, a drug discovery CRO; Investor Director at Fluidic Analytics, a spin out from Cambridge University; and Investor Director to Talking Medicines in Glasgow. Cons’s early pharma industry experience was with BayerSchering and GlaxoSmithKline.

Dr Marcus Yeo, Founder and Chief Executive Officer, commented: “On behalf of DefiniGEN and the Board of Directors, I am delighted to welcome Ben and look forward to drawing upon his strategic and operational expertise to accelerate business growth at this exciting time.”

Dr Cons is a renowned entrepreneur who designs, builds, and operates business solutions across the international pharmaceutical space to fast-track product development, maximize product lifecycle value and create optimum healthcare solutions.

By applying his expertise to the business, he will now aid DefiniGEN in further expanding its portfolio of gene-editing and stem cell capabilities in the preclinical drug development sector.

Dr Cons, newly appointed Chairman of the Board, commented: “I’m excited to join the board at this important stage in the company’s development. DefiniGEN’s unique iPSC platform technology has the potential to redefine drug discovery productivity via the provision of phenotypically relevant disease models and novel biological data set generation.”